Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Common Equity: 2022-2025

Historic Common Equity for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $43.7 million.

  • Orchestra BioMed Holdings' Common Equity fell 5.37% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 5.37%. This contributed to the annual value of $33.0 million for FY2024, which is 51.56% down from last year.
  • Orchestra BioMed Holdings' Common Equity amounted to $43.7 million in Q3 2025, which was up 14,726.78% from $295,000 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Common Equity high stood at $99.8 million for Q1 2023, and its period low was -$6.1 million during Q3 2022.
  • Moreover, its 3-year median value for Common Equity was $46.2 million (2024), whereas its average is $52.6 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Common Equity skyrocketed by 2,377.65% in 2023 and then plummeted by 99.33% in 2025.
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Common Equity stood at $52.5 million in 2022, then climbed by 29.52% to $68.0 million in 2023, then tumbled by 51.56% to $33.0 million in 2024, then dropped by 5.37% to $43.7 million in 2025.
  • Its last three reported values are $43.7 million in Q3 2025, $295,000 for Q2 2025, and $16.9 million during Q1 2025.